Compass Therapeutics, Inc. (CMPX) Financial Analysis & Valuation | Quarter Chart
Compass Therapeutics, Inc. (CMPX)
CMPXPrice: $5.66
Fair Value: 🔒
🔒score
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibo... more
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in ... more
Description
Shares
| Market Cap | $782.70M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Thomas J. Schuetz |
| IPO Date | 2021-04-05 | CAGR | — |
| Employees | 35 | Website | www.compasstherapeutics.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CMPX chart loading...
Fundamentals
Technicals
| Enterprise Value | $971.80M | P/E Ratio | -10.91 |
| Forward P/E | -4.71 | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 5.32 |
| P/CF Ratio | -21.29 | P/FCF Ratio | -15.92 |
| EPS | $-0.45 | EPS Growth 1Y | 24.58% |
| EPS Growth 3Y | 25.7% | EPS Growth 5Y | -13.46% |
| Revenue Growth 1Y | -100% | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.44% | ROA | -0.3% |
| ROCE | -0.27% | Current Ratio | 15.02 |
| Quick Ratio | 15.02 | Cash Ratio | 2.19 |
| Debt/Equity | 0.05 | Interest Coverage | — |
| Altman Z Score | 18.23 | Piotroski Score | 2 |